1 April 2026
Swissmedic: Publication of New FAQs on Risk Management for Human Medicinal Products
Swissmedic has issued a new FAQ document, effective 1 April 2026, providing structured guidance on key aspects of risk management for human medicinal products, including drug safety signals, PSURs, RMPs, and DHPCs. The FAQs aim to help marketing authorisation holders and stakeholders better understand the regulatory requirements and procedures.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting